Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study

類似資料

• Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
  著者:: Anderson, Michael S, 等
  出版事項: (2017)
• Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies
  著者:: Holmes, Anna D., 等
  出版事項: (2015)
• Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis
  著者:: Bewley, Anthony, 等
  出版事項: (2016)
• Erratum to: Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis
  著者:: Bewley, Anthony, 等
  出版事項: (2016)
• The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea
  著者:: Johnson, Andrew William, 等
  出版事項: (2015)